Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries

Financial Position - The company has no plans for a public or private offering at this time [1][3] - The company maintains a strong financial position with over $10 million in cash and no debt [1][3] - This fiscal strength allows the company to execute strategic initiatives and advance its pipeline without immediate need for additional financing [3] Clinical Trials - Enrollment in the HT-001 clinical trial is proceeding as planned, with all trial sites now active and enrolling participants [2][4] - HT-001 is the company's lead therapeutic candidate designed to treat rash and skin disorders associated with cancer therapy [4] - Activating all trial sites for HT-001 marks a significant milestone in the development of this promising therapy [5] Company Overview - Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative, patient-focused treatments [2][6] - The company is dedicated to improving patient quality of life through groundbreaking treatments [6] - Hoth collaborates with scientists, clinicians, and key opinion leaders to investigate therapeutics with potential for breakthroughs and diversified treatment options [6] Leadership Statement - The CEO emphasized the company's focus on creating long-term value and advancing clinical programs [4] - The company remains committed to addressing unmet needs for patients undergoing cancer treatment [5] - Hoth is dedicated to transparency and will provide updates as material developments occur [5]